Madrigal Pharmaceuticals Inc
MDGLNASDAQStock · Data from SEC EDGAR 13F · Held by 10 of 87 tracked investors
Madrigal Pharmaceuticals Inc at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation25
- Growth95
- Profitability5
- Quality20
- Debt100
- Stability60
- ✓It has more cash than debt.
- ✓The analysts' average target is 56% above the price.
- !The company is loss-making: net profit is negative.
- !The stock is expensive: you pay 45.7 USD for 1 USD of annual earnings.
The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.
Is the stock expensive?
Fairly expensiveThe company has no earnings, so the P/E cannot be calculated.
- P/E
- –
- P/S
- 7.9×
- EV/EBITDA
- -30.0×
Is the company growing?
–Too few years to compare. Last year 71.2%.
Does it make money?
Loss-making- Cost of sales 6
- Research 40.5
Earnings results
| Quarter | Reported | EPS | Analyst estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | 30 Jul 2026 | -1.99 | -2.55 | +22% |
| Mar 2026 | 6 May 2026 | -3.25 | -3.61 | +10% |
| Dec 2025 | 19 Feb 2026 | -2.57 | 0.04 | -6,525% |
| Sep 2025 | 4 Nov 2025 | -5.08 | -1.98 | -156.6% |
EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.
Chart MDGL
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
10JP John Paulson Paulson & Co | 27.94% |
SC Steven Cohen Point72 Asset Management | 0.08% |
JS Jim Simons Renaissance Technologies | 0.03% |
KG Ken Griffin Citadel Advisors | 0.03% |
IE Israel Englander Millennium Management | 0.02% |
PT Paul Tudor Jones Tudor Investment Corp | 0.01% |
JY Jeff Yass Susquehanna International Group | 0.01% |
Ns Norský státní fond Norges Bank | 0.01% |
Šn Švýcarská národní banka Swiss National Bank | 0.01% |
RB Ron Baron Baron Capital | 0% |
Frequently asked questions
How much is Madrigal Pharmaceuticals Inc (MDGL) stock?
Madrigal Pharmaceuticals Inc shares trade at $440.33, +0.59% over the last trading day. The price is delayed.
What is the market cap of Madrigal Pharmaceuticals Inc?
The market cap of Madrigal Pharmaceuticals Inc is about $10.2B.
Which big investors hold Madrigal Pharmaceuticals Inc?
According to the latest 13F filings, 10 of 87 tracked investors hold Madrigal Pharmaceuticals Inc, for example John Paulson, Steven Cohen, Jim Simons.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.